Shopping Cart 0
Cart Subtotal
USD 0

IDT Australia Ltd (IDT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

IDT Australia Ltd (IDT) is a contract manufacturing company that specializes in the development, scale-up and production of active pharmaceutical ingredients (APIs), microbiological and analytical testing, clinical trial research services and pharmacy services. The company also specializes in the post-discovery pharmaceutical life cycle. It manages Cytotoxic API's, high potency API's, anti-cancer drugs, antibiotics, anti-psychotics, beta lactams and controlled drugs. IDT provides a wide range of services, which can be customized to meet the specific requirements of its customer. The company also provides specialist clinical trial labeling, packaging and dispensing services. IDT is headquartered in Boronia, Victoria, Australia.

IDT Australia Ltd (IDT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

IDT Australia Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Asset Purchase 10

IDT Australia Acquires Generic Drugs from Global Generics Company for USD14.8 Million 10

IDT Australia to Acquire Synthetic Conjugated Estrogens from Perrigo 11

Partnerships 12

Mayne Pharma Enters into Distribution Agreement with IDT Australia 12

ANI Pharma Enters into Agreement with IDT Australia 13

Equity Offering 14

WellSpring Pharma Services Invests USD3 Million in IDT Australia 14

IDT Australia Completes Private Placement Of Shares For USD 2.8 Million 15

IDT Australia Completes Private Placement Of Shares For USD 0.8 Million 16

IDT Australia Completes Rights Offering Of Shares For USD 1.8 Million 17

Asset Transactions 18

ANI Pharma Acquires Generic ANDA Product Portfolio from IDT Australia for USD2.7 Million 18

I'rom Group Completes Acquisition of CMAX Clinical Trial Business from IDT Australia 19

Acquisition 21

I'rom Group to Acquire 61% Stake in CMAX from IDT Australia for USD7.6 Million 21

I'rom Completes Acquisition Of 18.8% Stake In IDT Australia For USD 2 Million 22

IDT Australia Ltd-Key Competitors 23

IDT Australia Ltd-Key Employees 24

IDT Australia Ltd-Locations And Subsidiaries 25

Head Office 25

Recent Developments 26

Financial Announcements 26

Aug 23, 2018: IDT Australia: Preliminary final report for the year ended 30 June 2018 26

Corporate Communications 27

Jul 02, 2018: IDT Australia Appoints Chief Executive Officer 27

Feb 16, 2018: IDT Australia Names Dr David Sparling As Interim Chief Executive Officer 28

Jun 13, 2017: IDT Australia: Dr Graeme Blackman AO retires 29

Legal and Regulatory 30

Jul 25, 2018: IDT Australia: FDA Meeting Update 30

Other Significant Developments 31

Jun 08, 2018: IDT Australia: Update on Response to Fda Warning Letter 31

Appendix 32

Methodology 32

About GlobalData 32

Contact Us 32

Disclaimer 32


List Of Figure

List of Figures

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

IDT Australia Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

IDT Australia Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

IDT Australia Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

IDT Australia Acquires Generic Drugs from Global Generics Company for USD14.8 Million 10

IDT Australia to Acquire Synthetic Conjugated Estrogens from Perrigo 11

Mayne Pharma Enters into Distribution Agreement with IDT Australia 12

ANI Pharma Enters into Agreement with IDT Australia 13

WellSpring Pharma Services Invests USD3 Million in IDT Australia 14

IDT Australia Completes Private Placement Of Shares For USD 2.8 Million 15

IDT Australia Completes Private Placement Of Shares For USD 0.8 Million 16

IDT Australia Completes Rights Offering Of Shares For USD 1.8 Million 17

ANI Pharma Acquires Generic ANDA Product Portfolio from IDT Australia for USD2.7 Million 18

I'rom Group Completes Acquisition of CMAX Clinical Trial Business from IDT Australia 19

I'rom Group to Acquire 61% Stake in CMAX from IDT Australia for USD7.6 Million 21

I'rom Completes Acquisition Of 18.8% Stake In IDT Australia For USD 2 Million 22

IDT Australia Ltd, Key Competitors 23

IDT Australia Ltd, Key Employees 24

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

IDT Australia Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

IDT Australia Ltd (IDT) is a contract manufacturing company that specializes in the development, scale-up and production of active pharmaceutical ingredients (APIs), microbiological and analytical testing, clinical trial research services and pharmacy services. The company also specializes in the post-discovery pharmaceutical life cycle. It manages Cytotoxic API's, high potency API's, anti-cancer drugs, antibiotics, anti-psychotics, beta lactams and controlled drugs. IDT provides a wide range of services, which can be customized to meet the specific requirements of its customer. The company also provides specialist clinical trial labeling, packaging and dispensing services. IDT is headquartered in Boronia, Victoria, Australia.

IDT Australia Ltd (IDT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

IDT Australia Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Asset Purchase 10

IDT Australia Acquires Generic Drugs from Global Generics Company for USD14.8 Million 10

IDT Australia to Acquire Synthetic Conjugated Estrogens from Perrigo 11

Partnerships 12

Mayne Pharma Enters into Distribution Agreement with IDT Australia 12

ANI Pharma Enters into Agreement with IDT Australia 13

Equity Offering 14

WellSpring Pharma Services Invests USD3 Million in IDT Australia 14

IDT Australia Completes Private Placement Of Shares For USD 2.8 Million 15

IDT Australia Completes Private Placement Of Shares For USD 0.8 Million 16

IDT Australia Completes Rights Offering Of Shares For USD 1.8 Million 17

Asset Transactions 18

ANI Pharma Acquires Generic ANDA Product Portfolio from IDT Australia for USD2.7 Million 18

I'rom Group Completes Acquisition of CMAX Clinical Trial Business from IDT Australia 19

Acquisition 21

I'rom Group to Acquire 61% Stake in CMAX from IDT Australia for USD7.6 Million 21

I'rom Completes Acquisition Of 18.8% Stake In IDT Australia For USD 2 Million 22

IDT Australia Ltd-Key Competitors 23

IDT Australia Ltd-Key Employees 24

IDT Australia Ltd-Locations And Subsidiaries 25

Head Office 25

Recent Developments 26

Financial Announcements 26

Aug 23, 2018: IDT Australia: Preliminary final report for the year ended 30 June 2018 26

Corporate Communications 27

Jul 02, 2018: IDT Australia Appoints Chief Executive Officer 27

Feb 16, 2018: IDT Australia Names Dr David Sparling As Interim Chief Executive Officer 28

Jun 13, 2017: IDT Australia: Dr Graeme Blackman AO retires 29

Legal and Regulatory 30

Jul 25, 2018: IDT Australia: FDA Meeting Update 30

Other Significant Developments 31

Jun 08, 2018: IDT Australia: Update on Response to Fda Warning Letter 31

Appendix 32

Methodology 32

About GlobalData 32

Contact Us 32

Disclaimer 32


List Of Figure

List of Figures

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

IDT Australia Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

IDT Australia Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

IDT Australia Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

IDT Australia Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

IDT Australia Acquires Generic Drugs from Global Generics Company for USD14.8 Million 10

IDT Australia to Acquire Synthetic Conjugated Estrogens from Perrigo 11

Mayne Pharma Enters into Distribution Agreement with IDT Australia 12

ANI Pharma Enters into Agreement with IDT Australia 13

WellSpring Pharma Services Invests USD3 Million in IDT Australia 14

IDT Australia Completes Private Placement Of Shares For USD 2.8 Million 15

IDT Australia Completes Private Placement Of Shares For USD 0.8 Million 16

IDT Australia Completes Rights Offering Of Shares For USD 1.8 Million 17

ANI Pharma Acquires Generic ANDA Product Portfolio from IDT Australia for USD2.7 Million 18

I'rom Group Completes Acquisition of CMAX Clinical Trial Business from IDT Australia 19

I'rom Group to Acquire 61% Stake in CMAX from IDT Australia for USD7.6 Million 21

I'rom Completes Acquisition Of 18.8% Stake In IDT Australia For USD 2 Million 22

IDT Australia Ltd, Key Competitors 23

IDT Australia Ltd, Key Employees 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

IDT Australia Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.